Sue Mahony to retire as president of Lilly Oncology

Eli Lilly’s senior vice president and president of Lilly Oncology, Sue Mahony, is set to retire at the end of August after 18 years of service with the company.

Mahony led Lilly Oncology through the integration of ImClone and launched several brands including Verzenio.

She also most recently led the refocusing of the company’s oncology R&D strategy.

Prior to this, as senior vice president of human resources and diversity, Mahony played in a role in restructuring the company into business units.

She said: “What I’ve appreciated over the years is the opportunity to participate in something greater than myself.

“We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”

Prior to her time with Eli Lilly, Mahony has served in various roles for Amgen, Bristol-Myers Squibb and Schering-Plough.

Lilly has said it is considering internal and external candidates to find Mahony’s successor.